American Banking and Market News logo

The Latest Headlines at American Banking and Market News

Image about Varonis Systems’ (VRNS) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Varonis Systems’ (VRNS) “Outperform” Rating Reaffirmed at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Varonis Systems (NASDAQ:VRNS – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. The brokerage currently has a $56.00... More of this article »
Image about UroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimer

UroGen Pharma (NASDAQ:URGN) PT Lowered to $34.00 at Oppenheimer

UroGen Pharma (NASDAQ:URGN – Free Report) had its price objective lowered by Oppenheimer from $35.00 to $34.00 in a research report released on Friday, Benzinga reports. The brokerage currently has an outperform rating on the... More of this article »
Image about Stifel Nicolaus Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Stifel Nicolaus Reaffirms Buy Rating for Viking Therapeutics (NASDAQ:VKTX)

Stifel Nicolaus reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research note published on Friday, Benzinga reports. The brokerage currently has a $80.00 price target on the biotechnology... More of this article »
Image about Verastem (NASDAQ:VSTM) Rating Reiterated by Royal Bank of Canada

Verastem (NASDAQ:VSTM) Rating Reiterated by Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Verastem (NASDAQ:VSTM – Free Report) in a report published on Friday morning, Benzinga reports. They currently have a $32.00 target price on the biopharmaceutical... More of this article »
Image about Viking Therapeutics’ (VKTX) “Buy” Rating Reiterated at HC Wainwright

Viking Therapeutics’ (VKTX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a research note released on Friday morning, Benzinga reports. They currently have a $90.00 price objective on the biotechnology... More of this article »
Image about Urgent.ly (NASDAQ:ULY) Price Target Cut to $5.00

Urgent.ly (NASDAQ:ULY) Price Target Cut to $5.00

Urgent.ly (NASDAQ:ULY – Free Report) had its price objective cut by Needham & Company LLC from $7.00 to $5.00 in a research note released on Friday, Benzinga reports. They currently have a buy rating on the stock. Urgent.ly... More of this article »
Image about CarGurus (NASDAQ:CARG) Price Target Raised to $27.00

CarGurus (NASDAQ:CARG) Price Target Raised to $27.00

CarGurus (NASDAQ:CARG – Free Report) had its target price raised by UBS Group from $26.00 to $27.00 in a report issued on Friday morning, Benzinga reports. The brokerage currently has a neutral rating on the stock. CARG has been... More of this article »
Image about AssetMark Financial Holdings, Inc. (NYSE:AMK) Short Interest Update

AssetMark Financial Holdings, Inc. (NYSE:AMK) Short Interest Update

AssetMark Financial Holdings, Inc. (NYSE:AMK – Get Free Report) was the target of a significant growth in short interest in February. As of February 29th, there was short interest totalling 254,500 shares, a growth of 11.4%... More of this article »
Image about Viking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from Maxim Group

Viking Therapeutics (NASDAQ:VKTX) Receives Buy Rating from Maxim Group

Maxim Group reaffirmed their buy rating on shares of Viking Therapeutics (NASDAQ:VKTX – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $120.00 price target on the biotechnology company’s... More of this article »
Image about Short Interest in Kenvue Inc. (NYSE:KVUE) Grows By 11.5%

Short Interest in Kenvue Inc. (NYSE:KVUE) Grows By 11.5%

Kenvue Inc. (NYSE:KVUE – Get Free Report) saw a significant increase in short interest during the month of February. As of February 29th, there was short interest totalling 24,910,000 shares, an increase of 11.5% from the February... More of this article »
Image about HC Wainwright Reiterates “Buy” Rating for Vir Biotechnology (NASDAQ:VIR)

HC Wainwright Reiterates “Buy” Rating for Vir Biotechnology (NASDAQ:VIR)

HC Wainwright reiterated their buy rating on shares of Vir Biotechnology (NASDAQ:VIR – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. HC Wainwright currently has a $110.00 target price... More of this article »
Image about Atlas Lithium Co. (NASDAQ:ATLX) Short Interest Up 11.5% in February

Atlas Lithium Co. (NASDAQ:ATLX) Short Interest Up 11.5% in February

Atlas Lithium Co. (NASDAQ:ATLX – Get Free Report) was the recipient of a large growth in short interest in the month of February. As of February 29th, there was short interest totalling 216,500 shares, a growth of 11.5% from... More of this article »
Image about Coinbase Global (NASDAQ:COIN) Price Target Raised to $150.00

Coinbase Global (NASDAQ:COIN) Price Target Raised to $150.00

Coinbase Global (NASDAQ:COIN) had its target price hoisted by JPMorgan Chase & Co. from $95.00 to $150.00 in a report released on Friday morning, Benzinga reports. The brokerage currently has a neutral rating on the cryptocurrency... More of this article »
Image about IES Holdings, Inc. (NASDAQ:IESC) Sees Significant Increase in Short Interest

IES Holdings, Inc. (NASDAQ:IESC) Sees Significant Increase in Short Interest

IES Holdings, Inc. (NASDAQ:IESC – Get Free Report) was the target of a significant increase in short interest during the month of February. As of February 29th, there was short interest totalling 86,800 shares, an increase of... More of this article »
Image about HC Wainwright Lowers Co-Diagnostics (NASDAQ:CODX) Price Target to $2.50

HC Wainwright Lowers Co-Diagnostics (NASDAQ:CODX) Price Target to $2.50

Co-Diagnostics (NASDAQ:CODX – Free Report) had its price objective cut by HC Wainwright from $3.00 to $2.50 in a research report report published on Friday morning, Benzinga reports. They currently have a neutral rating on the... More of this article »